Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Oncology

Latest News

July 20th 2016

The Value of a 21-Gene Test in Early-Stage Breast Cancer

By Surabhi Dangi-Garimella, PhD

During a health policy session at the annual meeting of the American Society of Clinical Oncology, Steven J. Katz, MD, MPH, discussed the Oncotype DX Breast Cancer Assay, and it's impact on recommendations for chemotherapy in early-stage breast cancer.

Cancer Drug Prices Follow a Sharp Upward Trajectory Post Launch

By Surabhi Dangi-Garimella, PhD

Evidence Lacking on Relation Between IVF and Long-Term Risk of Breast Cancer

By Surabhi Dangi-Garimella, PhD

Mismatch Repair Deficiency an Ideal Marker to Initiate Precision Care in CRC

By Surabhi Dangi-Garimella, PhD

Weighing the Value of Treatments in CLL

Latest Videos

Impact of Consolidation on the Value of Care Delivery

Impact of Consolidation on the Value of Care Delivery

Limitations of ICER's Value Assessment Framework Tool

Limitations of ICER's Value Assessment Framework Tool

Evidence Blocks: Patient Versus Societal Costs

Evidence Blocks: Patient Versus Societal Costs

The ASCO Value Framework as a Tool for Shared Decision Making

The ASCO Value Framework as a Tool for Shared Decision Making

Using the DrugAbacus Value Calculator

Using the DrugAbacus Value Calculator

The NCCN Evidence Blocks

The NCCN Evidence Blocks

Can Oncologists Perceive the Value of a Treatment?

Can Oncologists Perceive the Value of a Treatment?

Filling the Data Gaps, Improving Patient Understanding

Filling the Data Gaps, Improving Patient Understanding

Data Fragmentation: A Barrier to Value Constructs

Data Fragmentation: A Barrier to Value Constructs

Evaluating the Quality of Evidence Used for Developing Value Frameworks

Evaluating the Quality of Evidence Used for Developing Value Frameworks

More News

Influence of Treatment Modality on Outcomes in CLL

July 18th 2016

Diagnostic Testing and Evidence-Based Treatment in Cancer Care

July 18th 2016

Unmet Needs and the Increased Use of Targeted Therapy in CLL

July 18th 2016

Outcomes From the RESONATE 2 and HELIOS Trials - Clinical Impact

July 18th 2016

Value of Real-World Data in CLL Treatment

July 18th 2016

Looking to the Future in CLL Treatments

July 18th 2016

Safety and Efficacy Considerations in CLL

July 18th 2016

Safety of CLL Treatment and Reimbursement

July 18th 2016

The Changing Treatment Paradigm in CLL

July 18th 2016

How Do Payers Assess Value of Treatments in CLL?

July 18th 2016

Expanding Options in Treating CLL

July 18th 2016

Treatment Options for Older Patients With CLL

July 18th 2016

Patient Selection for Treatment With Ibrutinib in CLL

July 18th 2016

RESONATE-2 Trial: Safety and Efficacy Updates

July 18th 2016

Efficacy and Safety Considerations to Improve the Value of Treatment in CLL

July 18th 2016

Impact of Novel Agents on Coverage Decisions in CLL

July 18th 2016

Factors That Influence Up-front Therapy and Sequencing in CLL

July 18th 2016

Combination Treatments in CLL

July 18th 2016

Flexibility in Treatment Options for CLL

July 18th 2016

Pathophysiology, Prognostic Factors, and Potential Risks That Influence Treatment in CLL

July 18th 2016

Impact of Major Trials on CLL Treatment

July 18th 2016

Health Plans Encourage Use of Diagnostic Tests in CLL

July 18th 2016

Increased Use of Targeted Therapies in CLL

July 18th 2016

Pathophysiology and Treatment Landscape of CLL

July 18th 2016

UIC Study Supports Use of Adjuvant Chemotherapy in Stage II Colon Cancer

BySurabhi Dangi-Garimella, PhD

July 18th 2016

According to the study published in Cancer, adjuvant chemotherapy in patients with early stage colon cancer results in clinically relevant improvement in overall survival.

Trending on AJMC

Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata

First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA

5 Notable Oncology FDA Approvals Granted in May

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years

Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story